Welcome to Iceni Diagnostics in the Innovation Hub.
Find out about: Rapid & accurate diagnostics for viral disease | Gives a ‘yes’ or ‘no’ answer in under fifteen minutes | Current priorities are equine flu and avian flu | Technology also applicable to coronavirus, human influenza & norovirus
Iceni Diagnostics identifying viruses with sugars
Iceni Diagnostics is developing rapid, accurate tests for viral infections that mimic the process a virus uses to identify its host. It provides a yes/no answer in less than 15 minutes and can be used to detect a range of diseases with minimal training.
One of the priorities for the company is equine flu. An outbreak of this disease last year resulted in the loss of many racing events and millions of pounds of revenue. The availability of a rapid test that could have identified affected horses before they left the stable could have helped prevent the spread of this disease.
Iceni Diagnostics is a leader in diagnostics based on glycan recognition.
A spinout from the University of East Anglia and the John Innes Centre, it was founded by Professors David Russell and Rob Field, both internationally recognised for their contribution to glycoscience.
Watch the presentation below to find out more about how the test works and its uses.
Join the conversation or drop a question below for Iceni Diagnostics
Submit a question via email using the form below
More information and news about Iceni Diagnostics
Iceni Diagnostics was established in 2014 by Professor Rob Field, a world expert in glycan science and Director of the Manchester Institute of Biotechnology, and President of the Chemistry Biology Interface Division of the Royal Society of Chemistry, and Professor David Russell CSO, Emeritus Professor of Chemistry at UEA and founder of Intelligent Fingerprinting.
Iceni Diagnostics is currently in an investment round to support the validation and roll out the commercial launch of its initial product portfolio. It is also looking at additional funds from EU and BARDA.
In an industry dominated by protein/DNA technology the glycan-based platform offers opportunities for the development of novel medicines and tests.